Vivanza Biosciences Ratios

Vivanza Biosciences Ltd Ratios

The Vivanza Biosciences Ltd Ratios page provides a complete fundamental analysis of Vivanza Biosciences Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Vivanza Biosciences Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Vivanza Biosciences Ltd (NSE: , BSE: 530057) is currently trading at ₹2.07, with a market capitalization of ₹84M. As a major player in the Health technology sector and Pharmaceuticals: major industry, Vivanza Biosciences Ltd remains a key stock for fundamental analysis using Vivanza Biosciences Ltd Ratios.

Vivanza Biosciences Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Vivanza Biosciences Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Vivanza Biosciences Ltd Ratios.

Historically, the Vivanza Biosciences Ltd P/E ratio has shown strong fluctuations:

• 2024: 0
• 2023: 49.63
• 2022: 125.67
• 2021: 226.74
• 2020: 694.68

The decline in Vivanza Biosciences Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Vivanza Biosciences Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.01.

Historical P/B trend:

• 2024: 2.01
• 2023: 5.86
• 2022: 18.38
• 2021: 21.61

Vivanza Biosciences Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Vivanza Biosciences Ltd P/S ratio currently stands at 1.07, an important part of Vivanza Biosciences Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 1.07
• 2023: 0.98
• 2022: 4.22
• 2021: 7.26

The rising Vivanza Biosciences Ltd P/S ratio indicates improved revenue valuation by investors.

Vivanza Biosciences Ltd Price to Cash Flow Ratio (P/CF)

The Vivanza Biosciences Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.

Historical Vivanza Biosciences Ltd Price to Cash Flow Ratio:

• 2024: 0
• 2023: 71.16
• 2022: 0
• 2021: 0
• 2020: 0

The declining Vivanza Biosciences Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Vivanza Biosciences Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Vivanza Biosciences Ltd EV currently stands at ₹164.95M, representing the total company valuation including debt.

Historical EV trend:

• 2024: 164.95M
• 2023: 321.63M
• 2022: 830.56M
• 2021: 809.13M

Vivanza Biosciences Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Vivanza Biosciences Ltd EV/EBITDA ratio is currently 0, a key metric in Vivanza Biosciences Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 0
• 2023: 30
• 2022: 119.54
• 2021: 1150

Stable Vivanza Biosciences Ltd EV/EBITDA indicates balanced valuation.

Vivanza Biosciences Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Vivanza Biosciences Ltd D/E ratio is currently 2.18, reflecting leverage and financial stability.

Historical D/E:

• 2024: 2.18
• 2023: 1.11
• 2022: 1.95
• 2021: 1.58

Higher D/E ratio indicates rising financial risk.

Return on Equity (ROE %)

The Vivanza Biosciences Ltd ROE currently stands at -15.67%, showing profitability and capital efficiency.

Historical ROE:

• 2024: -15.67
• 2023: 12.54
• 2022: 15.78
• 2021: 10.01

Declining ROE indicates pressure on profitability.

Vivanza Biosciences Ltd Ratios Analysis Summary

The Vivanza Biosciences Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Vivanza Biosciences Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Vivanza Biosciences Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.